Detecting low levels of cancer after treatment using advanced blood tests
Genome-wide mutational integration for ultra-sensitive plasma tumor burden monitoring in immunotherapy
This study is looking at a new way to help people who have been treated for cancer by using a blood test to find tiny amounts of leftover cancer cells, which could lead to earlier treatment and better chances of staying cancer-free.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11088188 on NIH RePORTER |
What this research studies
This research focuses on improving cancer diagnostics by developing a method to detect minimal residual disease (MRD) in patients who have undergone treatment for cancer. The approach utilizes liquid biopsies to analyze circulating tumor DNA (ctDNA) in the blood, which can indicate the presence of remaining cancer cells. By employing a novel technique called MRDetect, the research aims to enhance the sensitivity of ctDNA detection, allowing for earlier intervention and optimization of therapies. This could significantly improve patient outcomes by preventing cancer recurrence.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who have recently undergone surgery or treatment and are at risk of minimal residual disease.
Not a fit: Patients with advanced cancer who are not undergoing treatment or those without a history of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective monitoring of cancer patients, allowing for timely adjustments in treatment to prevent cancer recurrence.
How similar studies have performed: Other research has shown promise in using liquid biopsies for cancer detection, indicating that this approach could be a significant advancement in the field.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Landau, Dan — Weill Medical Coll of Cornell Univ
- Study coordinator: Landau, Dan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.